Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights

Steve Vucic, Ulf Ziemann, Andrew Eisen, Mark Hallett, Matthew C Kiernan

ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder of the motor neurons in the motor cortex, brainstem and spinal cord. A combination of upper and lower motor neuron dysfunction comprises the clinical ALS phenotype. Although the ALS phenotype was first observed by Charcot over 100 years ago, the site of ALS onset and the pathophysiological mechanisms underlying the development of motor neuron degeneration remain to be elucidated. Transcranial magnetic stimulation (TMS) enables non-invasive assessment of the functional integrity of the motor cortex and its corticospinal projections. At date, TMS studies have established motor cortical and corticospinal dysfunction in ALS, with cortical hyperexcitability being an early feature in sporadic forms of ALS and preceding the clinical onset of familial ALS. Taken together, a central origin of ALS is supported by TMS studies, with an anterograde transsynaptic mechanism implicated in ALS pathogenesis. Of further relevance, TMS techniques reliably distinguish ALS from mimic disorders, despite a compatible peripheral disease burden, thereby suggesting a potential diagnostic utility of TMS in ALS. This review will focus on the mechanisms underlying the generation of TMS measures used in assessment of cortical excitability, the contribution of TMS in enhancing the understanding of ALS pathophysiology and the potential diagnostic utility of TMS techniques in ALS.

INTRODUCTION
The term amyotrophic lateral sclerosis (ALS) was first coined by Charcot, who postulated the primacy of the upper motor neuron (UMN) in ALS pathogenesis. Assessment of cortical function in ALS and identification of the characteristic clinical phenotype involving combined upper and lower motor neuron abnormalities remain the key for ALS diagnosis. However, despite Charcot’s initial observations, the site of disease onset and mechanisms underlying ALS pathophysiology remain areas of intense study and debate. In this setting, assessment of motor cortical and corticospinal function using non-invasive techniques, such as transcranial magnetic stimulation (TMS), has enhanced our understanding of ALS pathophysiology and resulted in novel diagnostic approaches. Single-, paired- and multiple-pulse TMS techniques have all been used (figure 1) with the following measures taken to reflect corticospinal neuronal function: motor threshold (MT), motor evoked potential (MEP) amplitude, central motor conduction time (CMCT), cortical silent period (CSP), intracortical inhibition and facilitation. The present review will focus on the mechanisms underlying the generation of these TMS measures, while at the same time assessing the contributions TMS has made in the understanding of ALS pathophysiology. With an eye towards the future, the review will also consider the potential diagnostic utility of TMS in ALS and incorporation of TMS as a disease biomarker in the assessment of neuroprotective medications in a clinical trial setting.

BACKGROUND TMS TERMINOLOGY AND PATHOPHYSIOLOGY
MT reflects the ease with which corticomotoneuronal neurons are excited and is proposed to be assessed by the International Federation of Clinical Neurophysiology as the minimum stimulus intensity required to elicit a small (usually >50 μV) MEP in the target muscle in 50% of trials. With the recent adaptation of threshold tracking techniques, MT can also be measured as the stimulus intensity required to elicit and maintain a target MEP response of 0.2 mV. MT reflects the density of corticospinal projections onto the spinal motor neuron with the highest density of projections to intrinsic hand muscles having the lowest MTs. MT is also be measured as the stimulus intensity required to elicit and maintain a target MEP response of 0.2 mV. MT reflects the density of corticospinal projections onto the spinal motor neuron with the highest density of projections to intrinsic hand muscles having the lowest MTs. MT is lower in the dominant hand and correlates with the ability to perform fine (fractionated) finger tasks, so that MT has the potential to map corticospinal neuronal representation and function. As well as reflecting the density of corticospinal neuronal projections, MTs may also be a biomarker of cortical neuronal membrane excitability. MTs are influenced by the glutamatergic neurotransmitter system, through α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, whereby excessive glutamate activity reduces MT. In contrast, pharmacological blockade of voltage-gated sodium channels raises MT. In ALS, abnormalities in MT have been inconsistent. Some TMS studies reported an increased MT in ALS or even an inexcitable motor cortex, whereas others have demonstrated either normal or reduced MT. These discrepancies likely relate to heterogeneity of the ALS phenotype and the stage of disease at time of testing and rate of progression. Longitudinal studies have documented a reduction of MTs in ALS patients with progressive fasciculations, preserved muscle bulk and hyper-reflexia. Fasciculations may precede other features of ALS by many months and taken in association with reduced

To cite: Vucic S, Ziemann U, Eisen A, et al. J Neurol Neurosurg Psychiatry 2013;84:1161–1170.
MT suggest a cortical origin of fasciculations in ALS. Reduced MT may be modulated by increased glutamate excitation, reduced gamma-Aminobutyric acid (GABA) inhibition or a combination of both. Reduced MT early in ALS supports an anterograde transsynaptic process, whereby cortical hyperexcitability underlies the development of progressive neurodegeneration.

MEP amplitude reflects a summation of complex corticospinal volleys consisting of D (direct-) and I (indirect)-waves. At threshold, TMS elicits I-waves at intervals of 1.5 ms, which increase in amplitude with increasing stimulus intensity. The increase in MEP amplitude with increasing stimulus intensity may be used to generate a stimulus–response curve that follows a sigmoid function. As with MT, the MEP amplitude reflects the density of corticomotoneuronal projections onto motor neurons. When compared with MT, the MEPs probably assess the function of neurons that are less excitable or further away from the centre of the TMS induced electrical field. The MEP amplitude should be expressed as a percentage of the maximum compound muscle action potential (CMAP) evoked by electrical peripheral nerve stimulation. Doing so takes into account any lower motor neuron pathology and provides insight into the percentage of the motor neurone pool activated in the MEP. Normative values for the MEP to CMAP ratio demonstrate a large inter-subject variability thereby reducing the sensitivity and limiting the value of this measure for detecting abnormalities of the corticomotoneurons.

The MEP responses are modulated by a variety of neurotransmitter systems within the central nervous system. Specifically, GABAergic neurotransmission via GABA_A receptors suppresses while glutamatergic and noradrenergic neurotransmission enhances the MEP amplitude. Of interest, these changes in MEP amplitude occur independently of changes in MT, suggesting that physiological mechanisms underlying the generation of the MEP amplitude and MT are varied.

Figure 1  Transcranial magnetic stimulation excites a network of neurons in the underlying motor cortex with motor evoked potentials recorded over the contralateral abductor pollicis brevis muscle. The motor cortex is preferentially stimulated when the current flows in a posterior–anterior direction within the motor cortex.

1162 Vucic S, et al. J Neurol Neurosurg Psychiatry 2013;84:1161–1170. doi:10.1136/jnnp-2012-304019
Abnormalities of MEPs have been extensively documented in ALS. Increases in MEP amplitude have been reported in sporadic and familial forms of ALS (figure 2A), most prominently early in the disease course. MEP amplitude correlates with surrogate biomarkers of axonal degeneration, such as the strength duration time constant, thereby providing an association between cortical hyperexcitability and motor neuron degeneration. The increase in MEP amplitude in ALS is not seen in mimic disorders despite a comparable degree of lower motor neuron dysfunction (figure 2B). This suggests that the MEP amplitude changes in ALS are excitotoxic in nature.

CMCT represents the time from stimulation of the motor cortex to the arrival of corticospinal volley at the spinal motor neuron. Multiple factors contribute to the CMCT including time to activate the corticospinal cells, conduction time of the descending volley down the corticospinal tract, synaptic transmission and activation of spinal motor neurons. CMCT may be measured using either the F-wave or cervical (or lumbar) nerve root stimulation methods; both methods provide only an estimation of the CMCT, and given that a variety of technical, physiological and pathological factors influence CMCT, there is a range of normative data.

In ALS, CMCT is typically modestly prolonged, probably reflecting axonal degeneration of the fastest conducting corticomotorneuronal fibres and increased desynchronisation of corticomotorneuronal volleys secondary to axonal loss. The D90A-SOD1 ALS mutation is a unique exception; in this disorder CMCT is typically very prolonged. The sensitivity of detecting a prolonged CMCT may be improved by recording from both upper and lower limb muscles, or from cranial muscles in ALS patients with bulbar onset disease.

CSP refers to the interruption of voluntary electromyography activity in a target muscle induced by stimulation of the contralateral motor cortex. The CSP duration is measured from the onset of the MEP response to resumption of voluntary electromyography activity and increases with stimulus intensity.

The CSP is mediated by both spinal mechanisms, in its early part, and cortical inhibitory neurons acting via GABAA receptors in the latter part. Since the duration is determined by the latter part, the CSP is a measure of cortical inhibition. In addition, the density of the corticomotorneuronal projections onto motor neurons also influences the CSP with the CSP duration being the longest for upper limb muscles.

Abnormalities of the CSP duration are well established in ALS. Absence or reduction in CSP duration has been reported in both sporadic and familial ALS, with the reduction of CSP duration being the most prominent early in the disease course. The reduction of CSP duration appears to be specific for ALS among neuromuscular disorders, being normal in X-linked bulbospinal muscular atrophy (Kenedy’s disease), acquired neuromyotonia and distal hereditary motor neuronopathy with pyramidal features. Although the mechanisms underlying CSP duration reduction in ALS remain to be established, decreased motor drive and reduced GABAergic inhibition, either due to degeneration of inhibitory interneurons or dysfunction of GABA receptors, may underlie the reduction of CSP duration in ALS.

An absent or delayed ipsilateral CSP has also been reported as an early abnormality in ALS. The ipsilateral CSP also depends on functioning of transcallosal glutamatergic fibres projecting onto inhibitory interneurons in the non-stimulated motor cortex and degeneration of these transcallosal fibres or their targeted inhibitory interneurons may account for abnormalities of the ipsilateral CSP in ALS.

**PAIRED-PULSE TMS TECHNIQUES**

The previous section has covered conventional TMS parameters that can be assessed through activation of the motor cortex by single impulses. Motor cortical excitability may also be assessed using paired-pulse techniques, in which a conditioning stimulus modulates the effect of a second test stimulus. Several different paired-pulse paradigms have been developed but short interval intracortical inhibition (SICI), intracortical facilitation (ICF) and long interval intracortical inhibition have been most frequently used in ALS clinical research as methods to determine cortical excitability.

To identify SICI and ICF, a subthreshold conditioning stimulus is typically delivered at predetermined time intervals prior to a suprathreshold test stimulus. In the early TMS paradigms, the conditioning and test stimuli were kept constant, and changes in the test MEP amplitude were evaluated. Typically, if the interstimulus interval (ISI) was between 1 and 5 ms, the test response was inhibited (SICI). Increasing the ISI to between 7 and 30 ms resulted in the facilitation of the test response (ICF).

By recording the descending corticospinal volleys through epidural electrodes at the level of the cervical spinal cord, it has been deduced that both SICI and ICF originate at the level of the motor cortex. Specifically, SICI is associated with a reduction in the number and amplitude of late I-waves, namely I2 and I3, with I-wave suppression remaining up to an ISI of 20 ms, which is the typical duration of the inhibitory postsynaptic potential mediated through GABA receptors. SICI and ICF appear to be physiologically distinct processes as evident by lower thresholds for activation of SICI and SICI remains independent of the direction of current flow in the motor cortex.

**Figure 2** (A) The motor evoked potential (MEP) amplitude, expressed as a percentage of compound muscle action potential (CMAP) response, is significantly increased in sporadic amyotrophic lateral sclerosis (ALS) and familial ALS (FALS) when compared with healthy controls. (B) The MEP amplitude is significantly increased in ALS when compared with pathological and healthy controls, thereby distinguishing ALS from ALS mimic disorders. **p<0.05; ***p<0.001. RMT, resting motor threshold.**
induced by a subthreshold conditioning pulse in healthy subjects, while ICF appears to be preferentially generated by current flowing in a posterior–anterior direction.\textsuperscript{73}

A limitation of the ‘constant stimulus’ paired-pulse technique has been the marked variability in MEP amplitudes with consecutive stimuli.\textsuperscript{71–75} To overcome this limitation, a threshold tracking technique was developed whereby a constant target MEP response (0.2 mV) was tracked by a test stimulus.\textsuperscript{7} Using threshold tracking, two phases of SICI were identified,\textsuperscript{7} 76–77 a smaller phase at ISI $\leq$ 1 ms and a larger phase at ISI 3 ms (figure 3A). Although synaptic neurotransmission through the GABA\textsubscript{A} receptor mediates the second phase of SICI,\textsuperscript{74} 78–80 the precise mechanisms underlying the first phase of SICI remain uncertain. It was initially suggested that the first phase of SICI reflected local excitability properties, particularly relative refractoriness of cortical axons, with resultant resynchronisation of cortico-cortical and corticomotoneuronal volleys.\textsuperscript{7} 81 Subsequently, it has been argued that synaptic processes best explain the development of the initial phase of SICI, possibly driven by activation of cortical inhibitory circuits that were distinct to those that mediated the later SICI phase.\textsuperscript{76–77} 82

A reduction or absence of SICI, together with an increase in ICF, indicative of cortical hyperexcitability has been documented in cohorts of sporadic and familial ALS patients (figure 3A).\textsuperscript{10–32} 44 45 83–85 Of relevance, cortical hyperexcitability appears to be an early feature in sporadic ALS, correlating with measures of subsequent peripheral neurodegeneration.\textsuperscript{86} In addition, cortical hyperexcitability appeared as an early feature in familial ALS due to mutations linked to the superoxide dismutase-1 (SOD-1) and fused in sarcoma (FUS) genes,\textsuperscript{31} preceding the clinical development of familial ALS (figure 3B).\textsuperscript{31}

Neuropathological studies in ALS have identified degeneration of inhibitory cortical interneurons\textsuperscript{89} and this could account for the reduction in SICI. Separately, glutamatergic–medicated excitotoxicity may also contribute to SICI reduction, as was suggested by partial correction of SICI abnormalities in ALS patients treated with the glutamate antagonist riluzole.\textsuperscript{87} A recent study documenting SICI reduction at low (40\% of resting MT (RMT)), medium (70\% of RMT) and high (90\% of RMT) conditioning stimulus intensities in ALS patients provided further support for the notion that abnormalities in SICI appeared to be mediated by a combination of glutamate excitotoxicity and degeneration of inhibitory cortical circuits.\textsuperscript{80} As such, preserving the integrity of intracortical inhibitory circuits, and counteracting excitatory cortical circuits, may serve as potential therapeutic options in ALS.

**UTILITY OF PERISTIMULUS TIME HISTOGRAMS**

A peristimulus time histogram technique can assess the function of a select subset of corticomotoneurons by recording the perturbation of voluntarily recruited motor units induced by a threshold cortical stimulation.\textsuperscript{53} In healthy controls, there is a well synchronised primary peak with a latency of approximately 20–30 ms recording from hand or forearm muscles.\textsuperscript{28–35} Analysis of this primary peak in disease states such as ALS provides information on corticomotoneuronal conduction time, the extent of desynchronisation of corticomotoneuronal descending volleys, the degree of corticomotoneuronal synaptic input onto the anterior horn cell and the timing of excitatory and inhibitory inputs to the motor neuron.\textsuperscript{33}

In ALS, the primary peak becomes desynchronised, prolonged in duration and delayed.\textsuperscript{28–31} In addition, the amplitude of the primary peak may be increased with additional subcomponents both suggestive of corticomotoneuronal hyperexcitability.\textsuperscript{13–15} These primary peak abnormalities appear early in ALS,
accompanied by reduced MTs. With progression of disease, there is prolongation and increased desynchronisation of the primary peak, findings possibly specific to ALS when compared with healthy controls and Kennedy’s disease.53 94

TRIPLE STIMULATION TECHNIQUE
Over recent years, collision techniques such as the triple stimulation technique (TST) have been used to reduced the degree of MEP desynchronisation which normally occurs following a single cortical stimulus.95 96 This complex technique is performed by first delivering a high-intensity magnetic stimulus to motor cortex followed by supramaximal electrical stimulation of the peripheral nerve supplying the target muscle at the wrist such that the descending corticomotoneuronal volley is ‘collided’ out by the antidromic action potentials. Collision takes place along the proximal segment of the peripheral nerve at the upper arm. A third stimulus is subsequently delivered to Erb’s point (axilla) after an appropriate delay, eliciting a highly synchronised motor response in those fibres in which the collision had occurred. The amplitude and area of this test CMAP response are compared with the response induced by the conditioned TST paradigm (Erb’s point-wrist–Erb’s point stimulation) yielding an amplitude ratio of >93% and area ratio of >92% in healthy controls.95 96

In ALS, the TST is sensitive at detecting subclinical corticomotoneuronal dysfunction.54 97 Corticomotoneuronal dysfunction was also reported in Kennedy’s disease using the TST technique,98 99 potentially limiting the diagnostic utility of TST in ALS. Recently, however, a combination of TST with single- and paired-pulse TMS techniques has reaffirmed the functional integrity of corticomotoneuronal tracts in Kennedy’s disease,100 and thereby the diagnostic utility of TST.

DIAGNOSTIC BIOMARKER IN ALS
Given the well documented TMS abnormalities in ALS patients, the TMS techniques may be of utility in the diagnostic process of ALS. Although UMN signs may be clinically evident in ALS, in some phenotypes such as the flail arm variant, this may not be the case, and detection of subclinical UMN dysfunction may facilitate the diagnosis.42 Abnormalities of cortical excitability, including an increase in MEP amplitude along with reduction of SICI and RMTs, have been reported in the flail-arm variant of ALS, underscoring the utility of TMS in detecting subclinical UMN dysfunction.42 Of further relevance, subclinical UMN dysfunction has been reported in progressive muscular atrophy (PMA),101–103 suggesting that PMA may be a phenotype of ALS. While corticomotoneuronal integrity was recently reported to be intact in PMA using a β-hand intermuscular coherence technique,104 assessment of cortical function with TMS techniques may be of diagnostic utility, especially in light of presence of subclinical UMN pathology in PMA.102 103

Importantly, single- and paired-pulse TMS techniques reliably distinguish ALS from the mimic disorders (table 1), hastening the diagnosis of ALS by up to 8 months.47 A reduction in averaged SICI, between ISI 1 and 7 ms, and peak SICI at ISI 3 ms were the most robust diagnostic TMS parameters, with the finding of absent SICI exhibiting a sensitivity of 97%.47 Of further relevance, TMS studies have established the presence of early and subclinical dysfunction of cortico-bulbar and cortico-respiratory tracts in ALS,26 105–107 thereby suggesting a potential diagnostic utility of bulbar and diaphragmatic MEP recordings. In addition, combining TMS with radiological techniques, such as MR spectroscopy, may further add to the diagnostic yield especially given the sensitivity of MR spectroscopy in detecting subclinical UMN dysfunction.108–110 Consequently, combining TMS techniques, in particular the recording of SICI as well as bulbar and diaphragmatic MEPs, together with radiological techniques, such as MR spectroscopy, may enable an earlier diagnosis of ALS and thereby commencement of neuroprotective therapies and recruitment into clinical trials.

In addition to its diagnostic utility, it has been suggested that TMS may exhibit a clinical utility in assessing disease progression in ALS.111 Specifically, longitudinal TMS studies in ALS patients reported a significant reduction in MEP amplitude, MT and CMCT, and suggested that reduction in MEP amplitude may be an objective biomarker of disease progression in ALS.111 In contrast, others have failed to document any significant longitudinal changes in TMS parameters, thereby arguing against TMS utility in the monitoring of disease progression in ALS.52 Prospective longitudinal studies are indicated to further clarify the role for TMS in monitoring disease progression in ALS.

CONCEPTS OF ALS PATHOPHYSIOLOGY
In his original writings, Charcot concluded that ALS was a disorder of the brain and that the lower motor neuron component resulted from a downstream affect. Not all his contemporaries agreed and in particular Gowers was adamant that the demise of upper and lower motor neurons were independent events. In the past 2 decades the site of ALS onset has been revisited, to a large extent precipitated by the advent of TMS. Three schools

Table 1 Transcranial magnetic stimulation (TMS) techniques in amyotrophic lateral sclerosis (ALS) mimic disorders

| Mimic disorder        | RMT    | MEP amplitude | CMCT  | CSP duration | SICI  | ICF  | TST          |
|-----------------------|--------|---------------|-------|--------------|-------|------|--------------|
| Kennedy’s disease     | Normal | Normal        | Normal| Normal       | Normal| Normal | Normal and abnormal |
| Acquired neuromyotonia| Normal | Normal        | Normal| Normal       | Normal| Normal | Not done     |
| DHMNP                 | Normal | Normal        | Normal| Normal       | Normal| Normal | Not done     |
| SMA                   | Normal | Increased     | Normal| Normal       | Normal| Normal | Not done     |
| FOSMN syndrome        | Normal | Normal        | Normal| Normal       | Normal| Normal | Not done     |
| Neuromuscular disorders*| Normal | Normal        | Normal| Normal       | Normal| Normal | Not done     |

Single-pulse TMS studies have established a normal resting motor threshold (RMT) and cortical silent period (CSP) duration in all ALS mimic disorders. The motor evoked potential (MEP) amplitude was reported to be increased in spinal muscular atrophy (SMA), a finding attributed to greater corticomotoneuronal projections onto the surviving motor neurons. In addition, the central motor conduction time (CMCT) was reportedly prolonged in distal hereditary motor neuropathy with pyramidal features (DHMNP), short interval intracortical inhibition (SICI) and intracortical facilitation (ICF), assessed by the paired-pulse TMS technique, have been universally normal in ALS mimic disorders. In contrast, triple stimulation techniques (TST) have been reportedly abnormal in Kennedy’s disease, suggesting subclinical upper motor neuron dysfunction, although a recent study has reaffirmed functional integrity of corticomotoneuronal tracts in Kennedy’s disease (see Utility of peristimulus time histograms section). Single- and paired-pulse techniques have also been normal in facial onset sensory motor neuronopathy (FOSMN) syndrome.

*Neuromuscular disorders include demyelinating neuropathy, myasthenia gravis, lead toxicity and Hirayama’s disease.
of thought have developed pertaining to the role of the UMN, and related pathophysiological processes in ALS: (i) ‘the dying forward’ hypothesis, (ii) ‘the dying back’ hypothesis and (iii) ‘the independent degeneration’ hypothesis (figure 4). While the site of disease onset in ALS remains uncertain, TMS studies have tended to favour a cortical origin, with excitotoxicity mediating motor neuron degeneration in ALS.\(^5\)\(^112\)

The dying forward hypothesis proposes that ALS is primarily a disorder of the corticomotoneurons, which connect monosynaptically with anterior horn cells.\(^113\) Corticomotoneuronal hyperexcitability was postulated to induce anterior horn cell degeneration transsynaptically via an anterograde glutamate-mediated excitotoxic process.\(^113\) Most TMS studies have demonstrated that cortical hyperexcitability is an early feature in sporadic and familial ALS, linked to motor neuron degeneration.\(^27\)\(^30\)\(^31\)\(^41\)\(^43\)\(^65\)\(^112\)\(^113\)\(^114\)\(^115\) In addition, longitudinal studies in asymptomatic SOD-1 mutation carriers revealed that cortical hyperexcitability developed prior to the clinical onset of ALS,\(^31\) also seen in the G93A SOD-1 mouse model.\(^116\) Of relevance, loss of parvalbumin-positive inhibitory interneurons in the motor cortex of ALS patients would contribute to the development of cortical hyperexcitability.\(^117\) In keeping with a cortical origin of ALS is the now accepted view that ALS and frontotemporal dementia (FTD) represent an overlapping continuum of origin of ALS.\(^118\)\(^119\)\(^120\)\(^121\) Genetic findings establishing that increased hexanucleotide repeat expansion in the first intron of C9ORF72 gene on chromosome 9p21 is associated with both ALS and FTD.\(^120\)\(^121\) Of further relevance, accumulation of TDP-43 ubiquitinated inclusions in anterior horn cells appears to be a pathological hallmark of ALS.\(^119\)\(^122\) Interestingly, identical TDP-43 inclusions may also be evident in cortical neurons within the frontal (Betz cells) and temporal lobes of ALS patients,\(^119\)\(^122\)\(^123\) underscoring the link between FTD and ALS, and thereby a cortical origin of ALS.

Of relevance, molecular approaches have provided further corroborating evidence for glutamate excitotoxicity in ALS. Specifically, a significant reduction in the expression and function of the astrocytic glutamate transporter, excitatory amino acid transporter 2 (EAAT2), has been reported in the SOD-1 mouse model and the motor cortex and spinal cord of ALS patients.\(^124\)–\(^128\) In addition, dysfunction of EAAT2 transporter appeared to be a preclinical feature in the SOD-1 mouse model.\(^129\)\(^130\) Further underscoring the importance of astrocytes in ALS pathophysiology are recent stem cell studies documenting that motor neuron degeneration appears to be initiated by dysfunction of astrocytes.\(^131\)

On the postsynaptic side, increased expression of glutamate receptors permeable to excessive influx of Na\(^+\) and Ca\(^{2+}\) ions\(^132\) have been reported in ALS,\(^133\)–\(^136\)\(^137\) potentially rendering the motor neurons more susceptible to glutamate excitotoxicity.\(^138\) Further support for a role for glutamate excitotoxicity has been indirectly provided by the clinical benefit of riluzole, a glutamate antagonist, in ALS patients.\(^139\)–\(^142\)

For the glutamate hypothesis to be a plausible mechanism of motor neuron degeneration, the issue of selectivity of motor neuron involvement in ALS, together with sparing of motor neurons in non-ALS conditions exhibiting cortical hyperexcitability,\(^18\) must be explained. A number of molecular features may render the motor neurons vulnerable to glutamate toxicity in ALS. First, motor neurons preferentially express glutamate receptors, such as the AMPA receptors, which are more permeable to influx of Ca\(^{2+}\) ions.\(^133\)\(^134\)\(^136\)\(^137\) In addition, motor neurons in ALS patients lack the intracellular expression of Ca\(^{2+}\) binding proteins parvalbumin and calbindin D28k, both required to buffer intracellular Ca\(^{2+}\).\(^143\)\(^144\) Aberrant activity of the inositol 1,4,5-triphosphate receptor type 2 receptor has been reported in ALS.\(^145\)\(^146\)\(^147\) thereby resulting in higher intracellular concentrations of Ca\(^{2+}\) within the motor neurons. Ultimately, an influx of Ca\(^{2+}\) ions through the ionotropic glutamate receptors NMDA occurs in the motor neurons,\(^147\)\(^148\)\(^149\) resulting in increased intracellular Ca\(^{2+}\) concentration and activation of Ca\(^{2+}\)-dependent enzymatic pathways that mediate neuronal death.\(^149\)–\(^151\) Glutamate excitotoxicity may also result in production of free radicals that can further damage intracellular organelles and thereby cause cell death.\(^152\)–\(^154\)

It could be argued that the finding of widespread fasciculations in ALS, an important diagnostic criterion,\(^155\) may argue against a dying forward mechanism given that fasciculations are thought to originate from the distal motor axon, are associated with abnormalities of sodium and potassium conductance, and may precede the onset of lower motor neuron dysfunction.\(^156\)–\(^162\) It seems unlikely that cortical hyperexcitability could lead to changes in distal axonal excitability that would result in widespread fasciculations. Importantly, a supraspinal mechanism for triggering fasciculations in ALS has been previously reported.\(^163\) In agreement with this notion are findings that fasciculations in ALS may originate at the level of the motor neuron cell body.\(^157\) As such, it could be hypothesised that hyperexcitability of descending motor pathways may contribute to generation of

![Image](http://jnnp.bmj.com/)

Figure 4 The dying forward and dying back hypothesis of amyotrophic lateral sclerosis (ALS). The ‘dying forward’ hypothesis proposed that ALS was primarily a disorder of the corticomotoneurons (highlighted in red), with anterior horn cell degeneration mediated via an anterograde glutamate-mediated excitotoxic process. In contrast, the dying back hypothesis proposes that ALS begins within the muscle or neuromuscular junction, with pathologies retrogradely transported from the neuromuscular junction to the cell body where these pathologies may exert their deleterious effects.
fasciculation in ALS, thereby providing additional support for a
dying forward process.

In conjunction with glutamate excitotoxicity, there is compelling
evidence that mitochondrial dysfunction may exert an important
role in the pathophysiology of ALS.163–168 Under conditions of excessive Ca2+ load, as may be evident with gluta-
tamate excitotoxicity,169 mitochondrial production of free radicals increases resulting in injury of critical neuronal cellular
proteins and DNA. Mitochondrial dysfunction may in turn enhance glutamate excitotoxicity by disrupting the normal
resting membrane potential, resulting in loss of the voltage-
dependent Mg2+-mediated block of NMDA receptor channels.170
From a therapeutic perspective, depaminoxole, a pharma-
cological agent that enhances mitochondrial function,171 was
effective in slowing ALS progression in a recent phase II trial.172
A phase III, multicentre, international trial was commenced
in March 2011 to determine the clinical efficacy of dep-
aminoxole in ALS (ClinicalTrials.gov-NCT01281189). Taken
further, it is anticipated that TMS studies will be used to deter-
mine the efficacy of depaminoxole in the modulation of cor-
toral excitability in an attempt to provide further insight into
ALS pathophysiology.

The dying back hypothesis proposes that ALS is primarily a
disorder of the lower motor neurons, with pathogens retro-
gradely transported from the neuromuscular junction to the cell
body where they exert their deleterious effects.173 Although
some pathological studies have indirectly supported a dying back process,174–176 no pathogens of any type have been identi-
ﬁed in relation to ALS. The presence of widespread dysfunction
within the frontal cortex, including the primary, supplementary
and prefrontal motor cortices in ALS, remains difﬁcult to recon-
cile with a dying back process.3 110 177 In addition, the absence
of central pathology in other lower motor neuron disorders
such as Kennedy’s disease or poliomyelitis provides a further
case against a dying back process.33 44

The independent degeneration hypothesis suggests that the
upper and lower motor neurons degenerate independently.178
Some 100 years after the original Gowers publication, neuro-
pathological studies provided support for the independent
degeneration hypothesis whereby the degeneration of upper and
lower motor neurons appeared to be independent.179 180 These
correlative morphological techniques, however, may be con-
founded by the anatomical and functional complexity of the
corticomotoneuronal system.181 In particular, there remains
considerable variability in the corticomotoneuronal to anterior
horn cell ratio, due to synaptic changes, and as such attempts to
correlate upper and lower motor neurons on autopsy studies
may not be meaningful.33

In addition to the three competing theories of ALS pathogenesis,
a prion-like propagation hypothesis has also been suggested.182
Speciﬁcally, the previously documented contiguous spread of
ALS5 183 could be explained by direct neuron-to-neuron transmis-
sion of pathogenic proteins via exosomes, deﬁned as small lipid
membranous microvesicles.182 The pathogenic exosomes could
spread in either a rostral direction, explaining the rostral-to-caudal
spread of ALS, or in a lateral–horizontal direction accounting for
the lateral-to-medial spread of disease. In addition, non-contiguous
propagation of ALS could also be explained by spread of patho-
genic proteins or toxic molecules through the blood or CSF via
exosomes.183,184 Interestingly, the genes implicated in ALS pathog-
ensis, including TDP-43 and FUS, possess a putative prion
domain.184 Although a prion-like propagation mechanism may
seem an attractive explanation for the spread of ALS, at present
there is no direct evidence to support such a process in ALS.

Future clinical utility of TMS

Although first described by Charcot some 150 years ago, the
pathophysiological mechanisms underlying ALS, variability, rate
of progression and site of disease onset remain obscure.
Objective assessment of UMN function in ALS remains a difﬁcult
task in clinical neurophysiology.185 While TMS is mainly used as
a clinical research tool, conducted in specialised neurophysio-
logical laboratories, there is an urgent need to objectively assess
UMN function in ALS. This has been underscored by the recent
Awaji diagnostic criteria.155 186 Although needle electromyogra-
phy is used by the criteria to objectively assess lower motor
neuron dysfunction, the detection of UMN involvement is based
solely on clinical examination. Much has recently been learnt
about ALS from MRI, especially diffusion tensor MRI, functional
imaging and network analysis,110 187–198 but these tools remain
prohibitively expensive, not readily available and may exhibit a
modest diagnostic sensitivity.190 Commercially available TMS
systems that will enable an objective assessment of UMN function
could be readily developed, facilitating the diagnosis of ALS.
Such TMS systems may result in the development of more func-
tional ALS biomarkers that could be used in future drug trials for
early patient recruitment and monitoring of drug efficacy.

Acknowledgements Funding support from the Motor Neuron Disease Research
Institute of Australia (MNDRIA), Sylvia and Charles Viertel Charitable Foundation
Clinical Investigator grant, Ramaciotti Foundation and National Health and Medical
Research Council of Australia (Project grant numbers 510233 and 1024915) is
gratefully acknowledged.

Contributors SV was involved in the design, research and writing of the review. UZ,
AE, MH and MK were involved in the design, critiquing and editing of the review.

Funding Support from the Motor Neuron Disease Research Institute of Australia
(MNDRIA), Sylvia and Charles Viertel Charitable Foundation Clinical Investigator
grant, Ramaciotti Foundation and National Health and Medical Research Council of
Australia (Project grant numbers 510233 and 1024915) is gratefully acknowledged.

Competing interests None.

Ethics approval Local ethics committee.

Provenance and peer review Commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially, and
license their derivative works on different terms, provided the original work is properly
 cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES

1. Charcot J, Joffroy A. Deux cas d’atrophie musculaire progressive avec lesion de
la substance grise et des faisceaux antero-lateraux de la moelle epiniere. Arch Physiol
Neural Pathol 1869;2:744–54.
2. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet
2011;377:942–55.
3. Vucic S, Burke D, Kiernan MC. Diagnosis of motor neuron disease. In: Kiernan
MC, ed. The motor neuron disease handbook. Sydney: Australasian Medical
Publishing Company Limited, 2009:89–115.
4. Winhammar JM, Rowe DB, Henderson RD, et al. Assessment of disease
progression in motor neuron disease. Lancet Neurology 2005;4:229–38.
5. Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at
the clinical onset of ALS. Neurology 2007;68:1571–5.
6. Rossini PM, Berardelli A, Deuschl G, et al. Pathophysiological mechanisms of
progression in motor neuron disease. Clin Neurophysiol 1999;52:171–85.
7. Fisher RJ, Nakamura Y, Bestmann S, et al. Two phases of intracortical inhibition
revealed by transcranial magnetic threshold tracking. Exp Brain Res
2002;143:240–8.
8. Vucic S, Howells J, Trevillian L, et al. Assessment of cortical excitability using
threshold tracking techniques. Muscle Nerve 2006;33:477–86.
9. Groppa S, Oliviero A, Eisen A, et al. A practical guide to diagnostic transcranial
magnetic stimulation: report of an IFCN committee. Clin Neurophysiol
2012;123:858–82.
10. Brouwer B, Ashby P. Corticospinal projections to upper and lower limb spinal
motorneurons in man. Electroencephalogr Clin Neurophysiol 1990;76:509–19.

Vucic S, et al. J Neurol Neurosurg Psychiatry 2013;84:1161–1170. doi:10.1136/jnnp-2012-304019
1167
11 Chen R, Tam A, Butefisch C, et al. Intracortical inhibition and facilitation in different representations of the human motor cortex. J Neurophysiol 1998;80:2870–81.

12 Macdonell RA, Shapiro BE, Chiappa KH, et al. Hemispheric threshold differences for motor evoked potentials produced by magnetic coil stimulation. Neurology 1991;41:1441–4.

13 Triggs WJ, Calvanio R, Levine M. Transcranial magnetic stimulation reveals a hemispheric asymmetry correlate of intermanual differences in motor performance. Neuropsychologia 1997;35:1335–63.

14 Amassian VE, Stewart M, Quirk GJ, et al. Motor cortex hyperexcitability is an early feature of motor neuron disease. J Neurol Neurosurg Psychiatry 1997;61:13–9.

15 Epstein CM, Schwartzberg DG, Davey KR, et al. Localizing the site of magnetic brain stimulation in humans. Neurology 1990;40:666–70.

16 Rudik D, Marg E. Finding the depth of magnetic brain stimulation: a re-evaluation. Electroencephalogr Clin Neurophysiol 1994;93:358–71.

17 D’I Laazzaro V, Oliverio A, Procleer P, et al. Ketamine increases human motor cortex excitability to 3(T) wave evoked potentials. J Neurosci 2003;23:547–56.

18 Ziemann U. TMS and drugs. Clin Neurophysiol 2004;115:1717–29.

19 Attarian S, Azulay JP, Lardillier D, et al. Transcranial magnetic stimulation in lower motor neuron diseases. Clin Neurophysiol 2005;116:35–42.

20 Berardelli A, Inghilleri M, Cruccu G, et al. Motor inhibition and excitation are independent effects of magnetic cortical stimulation. Neurology 1994;44:975–81.

21 Eisen A, Shytbel W, Murphy K, et al. State of the art: pharmacologic effects on motor inhibition and excitation. Muscle Nerve 2004;30:650–5.

22 de Carvalho M, Turkman A, Swash M. Motor responses evoked by transcranial magnetic stimulation and peripheral nerve stimulation in the ulnar innervation in amyotrophic lateral sclerosis: the effect of upper and lower motor neuron lesion. J Neurol Sci 2003;210:83–90.

23 Misioc G, Pisano F, Mora G, et al. Motor neuron disease: usefulness of transcranial magnetic stimulation in improving the diagnosis. Clin Neurophysiol 1999;110:975–81.

24 Triggs WJ, Macdonell RA, Crox D, et al. Motor inhibition and excitation are independent effects of magnetic cortical stimulation. Annals of Neurol 1992;32:345–53.

25 Triggs WJ, Menkes D, Onorato J, et al. Transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease. Neurology 1999;53:605–11.

26 Urban P, Wicht S, HofP. Sensitivity of transcranial magnetic stimulation of cortico-bulbar vs. cortico-spinal tract involvement in ALS. J Neurol 2001;248:3085–5.

27 Caramia MD, Cicinelli P, Paradiso C, et al. “Excitability changes of muscular responses to magnetic brain stimulation in patients with central motor disorders. Electroencephalogr Clin Neurophysiol 1991;81:234–50.

28 Kohara N, Kaji R, Kojima Y, et al. Abnormal excitability of the corticospinal pathway in patients with amyotrophic lateral sclerosis: a single motor unit study using transcranial magnetic stimulation. Electroencephalogr Clin Neurophysiol 1996;101:32–41.

29 Mills KR, Nithi KA. Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Muscle Nerve 1997;20:1345–51.

30 Vucic S, Kienman MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 2006;129:2436–46.

31 Vucic S, Nicholson GA, Kienman MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008;131:1540–50.

32 Zanette G, Tamburin S, Mangano M, et al. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin Neurophysiol 2002;113:1688–97.

33 Eisen A, Weber M. The motor cortex and amyotrophic lateral sclerosis. Muscle Nerve 2001;24:63–73.

34 Hirota N, Iino Y, Kojima K, et al. Complex fasciculations and their origin in amyotrophic lateral sclerosis and Kennedy’s disease. Muscle Nerve 2000;23:1872–5.

35 Di Lazzaro V, Restuccia D, Oliverio A, et al. Magnetic transcranial stimulation at intensities below active motor threshold activates intracortical inhibitory circuits. Exp Brain Res 1998;119:265–8.

36 Devanne H, Lavoie BA, Capaday C. Input-output properties and gain changes in the human corticospinal pathway. Exp Brain Res 1997;114:329–38.

37 Ziemann U. Cortical threshold and excitability measurements. In: Eisen A. ed. Clinical neurophysiology of motor neuron diseases handbook of clinical neurophysiology. Amsterdam: Elsevier 2004;317–35.

38 Chen R, Crox D, Curna A, et al. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFICN committee. Clin Neurophysiol 2008;119:504–32.

39 Hess CW, Mills KR, Murray NM, et al. Magnetic brain stimulation: central motor conduction studies in multiple sclerosis. Ann Neurol 1987;22:744–52.

40 Paulus W, Classen J, Cohen LG, et al. State of the art: pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation. Brain Stimul 2008;1:151–63.
Nakamura H, Kitagawa H, Kawaguchi Y, et al. Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. J Physiol (Lond) 1997;498:817–23.

Ziemann U, Rothwell JC, Ridding MC. Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol (Lond) 1996;496:873–81.

Di Lazzaro V, Oliverio A, Meglio M, et al. Direct demonstration of the effect of lorazepam on the excitability of the human motor cortex. Clin Neurophysiol 2000;111:794–9.

Kiers L, Cross D, Chiappa KH, et al. Variability of motor potentials evoked by transcranial magnetic stimulation. Electroencephalogr Clin Neurophysiol 1993;89:415–23.

Vucic S, Cheah BC, Krishnan AV, et al. The cortico-diaphragmatic pathway involvement in amyotrophic lateral sclerosis: neurophysiological, respiratory and clinical considerations. J Neurol Sci 2006;251:10–6.

Similowski T, Attali V, Bensimon G, et al. Diaphragmatic dysfunction and dyspnoea in amyotrophic lateral sclerosis. Eur Respir J 2000;15:352–7.

Urban PP, Vogt T, Hofp HC. Corticobulbar tract involvement in amyotrophic lateral sclerosis. A transcranial magnetic stimulation study. Brain 1998;121:1099–108.

Mitsumoto H, Ulmg AM, Pullman SL, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology 2007;68:1402–10.

Kaufmann P, Pullman SL, Shengu DC, et al. Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology 2004;62:1753–7.

Turner MR, Kiernan MC, Lehn PG, et al. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009;8:94–109.

Floyd AG, Yu QP, Piboobouruk P, et al. Transcranial magnetic stimulation in ALS: utility of central motor conduction tests. Neurology 2009;72:498–504.

Vucic S, Kim DS, Maughan M. Pathophysiology of degeneration in familial amyotrophic lateral sclerosis. Curr Mol Med 2009;9:255–72.

Eisen A, Kim S, Pant B. Amyotrophic lateral sclerosis (ALS): a phlogistic disease of the corticomotoneurone? Muscle Nerve 1992;15:219–24.

Desio M, Bernardi G, Hagi AH, et al. Transcranial magnetic stimulation of motor pathways directed to muscles supplied by cranial nerves in ALS. Clin Neurophysiol 2006;117:122–40.

Eisen A, Pant B, Stewart H. Cortical excitability in amyotrophic lateral sclerosis: a clue to pathogenesis. J Neurol Sci 1993;220:11–6.

Browne SE, Yang L, Dimauro JP, et al. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol Dis 2006;22:599–610.

Nihei K, Morimoto K, Kowal NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathologica 1993;86:55–64.

Lillo P, Hodges JR. Frontotemporal dementia and motor neuron disease: overlapping clinic-pathological disorders. J Clin Neurosci 2009;16:1131–5.

Neumann M, Sampathu DM, Kwong UK, et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science 2006;314:130–3.

Renton Alan E, Majounie E, Waite A, et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neurology 2011;77:257–68.

DeJesus-Hernandez M, Mackenzie IR, Bouley BD, et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neurology 2011;77:245–56.

Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem and Biophys Res Commun 2006;351:602–11.

Rothstein JD, Jin L, Dykes-Hoberg M, et al. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 1993;90:6991–5.

Rothstein JD, Van Kamm M, Levey A, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:78–84.

Troost D, Rolfs A, Danbolt NC, et al. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 1999;2:848.

Bostock-Howes W, Gibbs SL, Williams EO, et al. Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem 2006;281:14076–84.

Gibbs SL, Bostock-Howes W, Lavina ZS, et al. A Caspase-3-cleaved Fragment of the Glial Glutamate Transporter EAAT2 Is Sumoylated and Targeted to Promyelocytic Leukemia Nuclear Bodies in Mutant SOD1-Linked Amyotrophic Lateral Sclerosis. J Biol Chem 2007;282:32480–90.

Harid-Phillips AM, Hester ME, Miranda DJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotech 2011;29:824–8.

Simeone TA, Sanchez RM, Rho JM. Molecular biology and ontology of glutamate transporters in the mammalian central nervous system. J Child Neurol 2004;19:343–60.

Kawahara Y, To K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004;427:401.

Kwak S, Kawahara Y, Deficient RNA editing of GluR2 and neuronal death in amyotrophic lateral sclerosis. J Mol Med 2005;83:110–20.

Takuma H, Kwak S, Yosihawa T, et al. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 1996;46:806–15.
Neurodegeneration

136 Van Damme P, Braeken D, Callewaert G, et al. Glur2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. J Neurochem 2005;94:605–12.

137 Van Damme P, Van Den Bosch L, Van Houtte E, et al. Glur2-dependent properties of AMPA receptor subtypes determine the selective vulnerability of motor neurons to excitotoxicity. J Neuroscience 2002;22:1279–87.

138 Williams TL, Day NC, Ince PG, et al. Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1997;42:200–7.

139 Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1997;338:585–91.

140 Guney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1999;36:147–57.

141 Guney ME, Fleck TJ, Himes CS, et al. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1999;46:846–57.

142 Ince P, Stout N, Shaw P, et al. Selective motoneuron vulnerability in amyotrophic lateral sclerosis: a genome-wide association study. Neurology 2007;6:869.

143 Chung MJ, Suh YL. Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2005;64:716–24.

144 Lederer CW, Torrioli A, Pantelidou M, et al. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics 2007;8:26.

145 Xu Z, Jung C, Higgin C, et al. Mitochondrial degeneration in amyotrophic lateral sclerosis. J Bioenerg Biomembr 2004;36:395–9.

146 Dugan LL, Choi DW. Excitotoxicity, free radicals, and cell membrane changes. Ann Neurol 1994;35:517–22.

147 Heath PR, Tomkins J, Ince PG, et al. Quantitative assessment of AMPA receptor mRNA in human spinal motor neurons isolated by laser capture microdissection. Neuroreport 2002;13:1753–7.

148 Miller RJ, Murphy SN, Glaum SR. Neuronal Ca2+ channels and their regulation by ionic dependence of glutamate neurotoxicity. J Neurosci 2002;86:7770–86.

149 Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and excitatory amino acid neurotoxicity and glutamatergic hyperexcitability in amyotrophic lateral sclerosis. Ann Neurol 2002;51:608–18.

150 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

151 Pun S, Santos AF, Saxena S, et al. Selective vulnerability and pruning of phasic motorneuron axons in motoneuron disease alleviated by CN1T. Nat Neurosci 2009;12:608–18.

152 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

153 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

154 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

155 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

156 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

157 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

158 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

159 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

160 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

161 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

162 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

163 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

164 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

165 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

166 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

167 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

168 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.

169 Miller RG, Jackson CE, Karsakci E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227–33.